DE60318547D1 - Agonisten des corticotropin-freisetzenden faktor rezeptors 2 - Google Patents

Agonisten des corticotropin-freisetzenden faktor rezeptors 2

Info

Publication number
DE60318547D1
DE60318547D1 DE60318547T DE60318547T DE60318547D1 DE 60318547 D1 DE60318547 D1 DE 60318547D1 DE 60318547 T DE60318547 T DE 60318547T DE 60318547 T DE60318547 T DE 60318547T DE 60318547 D1 DE60318547 D1 DE 60318547D1
Authority
DE
Germany
Prior art keywords
agonists
factor receptor
releasing factor
corticotropin releasing
corticotropin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318547T
Other languages
English (en)
Other versions
DE60318547T2 (de
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Co LLC
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of DE60318547D1 publication Critical patent/DE60318547D1/de
Application granted granted Critical
Publication of DE60318547T2 publication Critical patent/DE60318547T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60318547T 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden faktor rezeptors 2 Expired - Lifetime DE60318547T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US349117P 2002-01-16
US37633702P 2002-04-29 2002-04-29
US376337P 2002-04-29
US38889502P 2002-06-14 2002-06-14
US388895P 2002-06-14
US41198802P 2002-09-19 2002-09-19
US411988P 2002-09-19
PCT/US2003/001451 WO2003062268A2 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists

Publications (2)

Publication Number Publication Date
DE60318547D1 true DE60318547D1 (de) 2008-02-21
DE60318547T2 DE60318547T2 (de) 2008-12-24

Family

ID=27617822

Family Applications (4)

Application Number Title Priority Date Filing Date
DE60321730T Expired - Lifetime DE60321730D1 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden Faktor Rezeptors 2
DE60313845T Expired - Lifetime DE60313845T2 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden faktor rezeptors 2
DE60318547T Expired - Lifetime DE60318547T2 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden faktor rezeptors 2
DE60307044T Expired - Lifetime DE60307044T2 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden faktor rezeptors 2

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60321730T Expired - Lifetime DE60321730D1 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden Faktor Rezeptors 2
DE60313845T Expired - Lifetime DE60313845T2 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden faktor rezeptors 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60307044T Expired - Lifetime DE60307044T2 (de) 2002-01-16 2003-01-16 Agonisten des corticotropin-freisetzenden faktor rezeptors 2

Country Status (30)

Country Link
US (7) US6936585B2 (de)
EP (4) EP1465922B1 (de)
JP (3) JP4508648B2 (de)
KR (3) KR100735586B1 (de)
CN (3) CN100475844C (de)
AR (3) AR038143A1 (de)
AT (4) ATE398632T1 (de)
AU (2) AU2003205197B2 (de)
BR (3) BR0306838A (de)
CA (3) CA2470731C (de)
CY (1) CY1106133T1 (de)
DE (4) DE60321730D1 (de)
DK (2) DK1465921T3 (de)
ES (4) ES2299701T3 (de)
HK (1) HK1078095A1 (de)
IL (5) IL162530A0 (de)
MA (3) MA27592A1 (de)
MX (3) MXPA04006884A (de)
MY (1) MY140306A (de)
NO (3) NO20043366L (de)
NZ (3) NZ533598A (de)
PE (3) PE20030849A1 (de)
PL (3) PL371364A1 (de)
PT (2) PT1465921E (de)
RU (1) RU2294333C2 (de)
SA (3) SA03230565B1 (de)
SI (1) SI1465921T1 (de)
TW (3) TWI300442B (de)
WO (3) WO2003062277A1 (de)
ZA (1) ZA200404995B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
EP1871888A4 (de) * 2005-03-30 2013-08-21 Novartis Vaccines & Diagnostic Haemophilus-influenzae vom typ b
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
US20100216722A1 (en) * 2007-09-11 2010-08-26 Dorian Bevec Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
RU2010114038A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
AU2009313619A1 (en) 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
EP2206726A1 (de) * 2009-01-08 2010-07-14 Universite Joseph Fourier Nichtinvasive Instrumente zum Nachweisen anfälliger atherosklerotischer Plaques
AU2010315131A1 (en) * 2009-11-04 2012-05-31 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
US9314506B2 (en) 2011-10-24 2016-04-19 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
HUE036640T2 (hu) * 2012-02-14 2018-07-30 Univ California Parakrin gének szisztémás bejuttatása és szabályozott expressziója szív és érrendszeri betegségekre és egyéb állapotokra
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
CA3040889A1 (en) * 2016-10-20 2018-04-26 Cortene Inc. Methods of treating diseases resulting from a maladapted stress response
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) * 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (de) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin freisetzende Rezeptoren des Faktor 2
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) * 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
WO1997000063A2 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) * 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
EP1305334B1 (de) 2000-08-04 2008-09-17 Research Development Foundation Urocortinproteine und deren verwendungen
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6936585B2 (en) 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
US7632933B2 (en) 2009-12-15
CA2470743A1 (en) 2003-07-31
HK1078095A1 (en) 2006-03-03
EP1724283A3 (de) 2007-04-11
DE60313845D1 (de) 2007-06-28
WO2003062268A3 (en) 2003-11-27
US20100197579A1 (en) 2010-08-05
US20060025339A1 (en) 2006-02-02
CA2470731A1 (en) 2003-07-31
PE20030974A1 (es) 2003-12-26
IL162530A0 (en) 2005-11-20
JP4508649B2 (ja) 2010-07-21
JP2005525101A (ja) 2005-08-25
SA03230564B1 (ar) 2006-10-31
KR100758858B1 (ko) 2007-09-14
DK1465921T3 (da) 2006-11-27
NZ533600A (en) 2007-02-23
ES2269976T3 (es) 2007-04-01
EP1465922A2 (de) 2004-10-13
MA27592A1 (fr) 2005-11-01
BR0306826A (pt) 2005-09-06
IL197774A0 (en) 2009-12-24
US20030148956A1 (en) 2003-08-07
EP1465921A2 (de) 2004-10-13
US20090124793A1 (en) 2009-05-14
US20030148958A1 (en) 2003-08-07
SA03230565B1 (ar) 2006-10-31
CY1106133T1 (el) 2011-06-08
KR20040082392A (ko) 2004-09-24
ATE362488T1 (de) 2007-06-15
NO20043366L (no) 2004-10-06
AR038143A1 (es) 2004-12-29
BR0306878A (pt) 2004-10-26
US7192924B2 (en) 2007-03-20
CA2470731C (en) 2011-06-21
PL371364A1 (en) 2005-06-13
PL373529A1 (en) 2005-09-05
BR0306838A (pt) 2005-04-05
AU2003205197B2 (en) 2006-03-02
CA2470743C (en) 2011-12-13
ATE398632T1 (de) 2008-07-15
EP1465923B1 (de) 2007-05-16
IL162431A0 (en) 2005-11-20
NZ533598A (en) 2007-03-30
WO2003062269A3 (en) 2003-11-06
PL373139A1 (en) 2005-08-22
US7462597B2 (en) 2008-12-09
ES2309909T3 (es) 2008-12-16
KR20040082389A (ko) 2004-09-24
PT1465921E (pt) 2006-12-29
CN100391972C (zh) 2008-06-04
JP4508648B2 (ja) 2010-07-21
US7897731B2 (en) 2011-03-01
US20030148957A1 (en) 2003-08-07
SA03230565A (ar) 2005-12-03
JP2005522191A (ja) 2005-07-28
CN1617887A (zh) 2005-05-18
WO2003062277A1 (en) 2003-07-31
CN100475844C (zh) 2009-04-08
EP1724283A2 (de) 2006-11-22
WO2003062268A2 (en) 2003-07-31
IL162529A0 (en) 2005-11-20
NO20043396L (no) 2004-10-06
MXPA04006884A (es) 2004-12-06
MXPA04006883A (es) 2004-12-06
CA2470656C (en) 2011-06-28
RU2004124847A (ru) 2005-04-20
EP1465921B1 (de) 2006-07-26
US7608701B2 (en) 2009-10-27
SA03230564A (ar) 2005-12-03
CN1617886A (zh) 2005-05-18
DE60307044T2 (de) 2007-02-15
PE20030849A1 (es) 2003-12-01
ATE383372T1 (de) 2008-01-15
US6936585B2 (en) 2005-08-30
ES2299701T3 (es) 2008-06-01
KR100758857B1 (ko) 2007-09-14
MA27591A1 (fr) 2005-11-01
ZA200404995B (en) 2005-06-29
AR038142A1 (es) 2004-12-29
RU2294333C2 (ru) 2007-02-27
EP1724283B1 (de) 2008-06-18
CA2470656A1 (en) 2003-07-31
NO20043371L (no) 2004-10-06
AU2003237419B2 (en) 2006-04-13
MA27590A1 (fr) 2005-11-01
EP1465922B1 (de) 2008-01-09
EP1465923A1 (de) 2004-10-13
US7192923B2 (en) 2007-03-20
TW200302277A (en) 2003-08-01
DE60313845T2 (de) 2008-01-31
PT1465923E (pt) 2007-08-06
KR100735586B1 (ko) 2007-07-04
MXPA04006885A (es) 2004-12-06
ATE334147T1 (de) 2006-08-15
JP4489434B2 (ja) 2010-06-23
TW200302276A (en) 2003-08-01
KR20040082390A (ko) 2004-09-24
DE60321730D1 (de) 2008-07-31
ES2287484T3 (es) 2007-12-16
AR038144A1 (es) 2004-12-29
US20080004435A1 (en) 2008-01-03
IL196384A0 (en) 2011-07-31
PE20030747A1 (es) 2003-10-23
DE60318547T2 (de) 2008-12-24
SI1465921T1 (sl) 2006-10-31
TWI300442B (en) 2008-09-01
WO2003062269A2 (en) 2003-07-31
TW200302278A (en) 2003-08-01
NZ533599A (en) 2007-03-30
DE60307044D1 (de) 2006-09-07
MY140306A (en) 2009-12-31
CN1617885A (zh) 2005-05-18
DK1465923T3 (da) 2007-07-02
JP2005521387A (ja) 2005-07-21

Similar Documents

Publication Publication Date Title
IL197774A0 (en) Corticotropin releasing factor 2 receptor agonists
NL1025148A1 (nl) Benzamideremmers van de P2X7-receptor.
EE200200400A (et) Kortikotropiini vabastava faktori antagonistid
ATE428685T1 (de) Aminosubstituierte ethylaminoagonisten des beta2- adrenergen rezeptors
IL163613A (en) Partial or full agonists of a1 adenosine receptors and pharmaceutical compositions comprising the same
DK1463759T3 (da) Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
DE60028368D1 (de) Agonisten des peroxisom aktivator-responsiven rezeptors
FR2835321B1 (fr) Monture d'objectif
HK1079776A1 (en) The synthesis of 1,3-dihydro-2h-3-benzazepin-2-onecompounds, and the use thereof
DE60326190D1 (de) des Körpers
DK1487778T3 (da) Substituerede 4 aminocyclohexanoler
ITPD20020251A1 (it) Dispositivo per l'ottimizzazione dell'innesto di
DE60303424D1 (de) D-Ring Halterung
ITAN20020022V0 (it) Gancio regolabile per quadri
FI20021674A0 (fi) Päällystyslaite
ITRM20030434A0 (it) Dispenser elettronico portatile per l'applicazione di etichette.
ZA200404994B (en) Corticotropin releasing factor 2 receptor agonists
AU2003300867A8 (en) Uses of the snorf207 receptor
SI1465923T1 (sl) Agonisti receptorja 2 faktorja sproščanja kortikotropina
AU2003297644A8 (en) Uses of the snorf55 receptor
ITAP20030005A1 (it) L'indimenticabile soluzione
SE0203227D0 (sv) The W/F/T-sens 1/3
ITMI20022678A1 (it) Negativoscopio con mezzi di mascheratura dell'area di
ITMI20032264A1 (it) Struttura di appendiabito particolarmente per ombrelloni e simili
ITRM20040388A1 (it) Pipino l'appaiacalzino

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WARNER CHILCOTT COMPANY, LLC, FAJARDO, P.R., US